Therapeutic upregulation of TGFBR3 in cardiac fibroblasts by simvastatin has been reported to elicit beneficial anti-fibrotic action on fibroblasts and improved cardiac function after myocardial infarction [28]. This evidence concerns the gene TGFBR3 and myocardial infarction.